Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $2.51 Million - $2.83 Million
8,788 New
8,788 $2.54 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $18.1 Million - $21.3 Million
-81,724 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $3.1 Million - $3.91 Million
17,487 Added 27.22%
81,724 $17.9 Million
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $149,646 - $167,466
-825 Reduced 1.27%
64,237 $11.7 Million
Q2 2021

Aug 06, 2021

BUY
$187.49 - $221.1 $5.79 Million - $6.82 Million
30,865 Added 90.26%
65,062 $13.1 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $3.21 Million - $3.74 Million
-15,513 Reduced 31.21%
34,197 $7.35 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $9.97 Million - $13.3 Million
48,173 Added 3134.22%
49,710 $11.7 Million
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $244,081 - $284,683
-1,675 Reduced 52.15%
1,537 $261,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $475,793 - $521,114
3,212
3,212 $488,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Magnetar Financial LLC Portfolio

Follow Magnetar Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Magnetar Financial LLC with notifications on news.